All In MedTech

Device Trial Radar · NCT05339126

RNS System LGS Feasibility Study

RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 4, 2022

Primary completion

Nov 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
NeuroPaceNot on our public-company list
Sponsor type
Industry
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS); University of Florida
First posted
Apr 21, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (LGS) who are refractory to antiseizure medications. The intent is to determine the feasibility and the optimal design of a subsequent pivotal study in order to expand the indication for use for the RNS System as a treatment for patients with medically intractable LGS.

Conditions

  • Epilepsy
  • Lennox Gastaut Syndrome
  • Lennox-Gastaut Syndrome, Intractable
  • Seizures
  • Seizures, Generalized

Interventions

  • RNS SystemDevice

    The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Annual device-related serious adverse event (SADE) rateTime frame: 12 months post-implant
  2. Safety: Annual device-related serious adverse event (SADE) rateTime frame: 24 months post-implant
  3. Effectiveness: Blinded evaluation period (BEP) responder rateTime frame: 12 months post-implant

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California, San Francisco

    San Francisco, California

  • Emory University

    Atlanta, Georgia

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.